M
Maud Maho-Vaillant
Researcher at French Institute of Health and Medical Research
Publications - 20
Citations - 1063
Maud Maho-Vaillant is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Rituximab & Pemphigus. The author has an hindex of 8, co-authored 15 publications receiving 796 citations. Previous affiliations of Maud Maho-Vaillant include University of Rouen.
Papers
More filters
Journal ArticleDOI
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Pascal Joly,Maud Maho-Vaillant,Catherine Prost-Squarcioni,Vivien Hébert,Estelle Houivet,Sébastien Calbo,Frédérique Caillot,Marie-Laure Golinski,Bruno Labeille,Catherine Picard-Dahan,Carle Paul,Marie-Aleth Richard,Jean-David Bouaziz,Sophie Duvert-Lehembre,Philippe Bernard,Frédéric Caux,Marina Alexandre,Saskia Ingen-Housz-Oro,Pierre Vabres,Emmanuel Delaporte,Gaëlle Quéreux,Alain Dupuy,Sébastien Debarbieux,Martine Avenel-Audran,Michel D'Incan,Christophe Bedane,Nathalie Beneton,Denis Jullien,Nicolas Dupin,Laurent Misery,Laurent Machet,Marie Beylot-Barry,Olivier Dereure,Bruno Sassolas,Thomas Vermeulin,Jacques Benichou,P. Musette +36 more
TL;DR: Data from this trial suggest that first-line use of rituximab plus short-termprednisone for patients with pemphigus is more effective than using prednisone alone, with fewer adverse events.
Journal ArticleDOI
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro.
Jean-David Bouaziz,Sébastien Calbo,Sébastien Calbo,Sébastien Calbo,Maud Maho-Vaillant,Maud Maho-Vaillant,Anne Saussine,Anne Saussine,Martine Bagot,Martine Bagot,Armand Bensussan,Armand Bensussan,Philippe Musette,Philippe Musette +13 more
TL;DR: It is implied that manipulating IL‐10 production by human B cells could be a useful therapeutic strategy for modulating immune responses in humans.
Journal ArticleDOI
Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
Natacha Colliou,Damien Picard,Frédérique Caillot,Sébastien Calbo,Stéphanie Le Corre,Annick Lim,Brigitte Lemercier,Brigitte Le Mauff,Maud Maho-Vaillant,Serge Jacquot,Christophe Bedane,Philippe Bernard,Frédéric Caux,Catherine Prost,Emmanuel Delaporte,Marie-Sylvie Doutre,Brigitte Dréno,Nathalie Franck,Saskia Ingen-Housz-Oro,Olivier Chosidow,Christine Pauwels,Catherine Picard,Jean-Claude Roujeau,M.-L. Sigal,E. Tancrede-Bohin,Isabelle Templier,Rüdiger Eming,Michael Hertl,Michel D'Incan,Pascal Joly,Philippe Musette +30 more
TL;DR: It is found that rituximab therapy can help pemphigus patients even after 6 years, in part by reshaping the B cell repertoire during reconstitution, allowing for long-term effects in addition to the short-term loss of pathogenic B cells.
Journal ArticleDOI
CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors.
Marie-Laure Golinski,Mélanie Demeules,Céline Derambure,Gaëtan Riou,Maud Maho-Vaillant,Olivier Boyer,Pascal Joly,Sébastien Calbo +7 more
TL;DR: It is reported that CD11c+ B cells are a distinct subpopulation of B cells, enriched in the memory subpopulation even if their phenotype is heterogeneous, with overexpression of genes involved in B-cell activation and differentiation as well as in antigen presentation.
Journal ArticleDOI
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
D.M. Chen,A. Odueyungbo,E. Csinady,L. Gearhart,P.B. Lehane,M. Cheu,Maud Maho-Vaillant,C. Prost‐Squarcioni,Vivien Hébert,Estelle Houivet,Sébastien Calbo,Frédérique Caillot,Marie-Laure Golinski,Bruno Labeille,Catherine Picard-Dahan,Carle Paul,Marie Aleth Richard,Jean-David Bouaziz,S. Duvert-Lehembre,P. Bernard,Frédéric Caux,M. Alexandre,Saskia Ingen-Housz-Oro,Pierre Vabres,Emmanuel Delaporte,Gaëlle Quéreux,Alain Dupuy,Sébastien Debarbieux,Martine Avenel-Audran,Michel D'Incan,Christophe Bedane,Nathalie Beneton,Denis Jullien,Nicolas Dupin,Laurent Misery,Laurent Machet,Marie Beylot-Barry,Olivier Dereure,Bruno Sassolas,Jacques Benichou,Philippe Musette,Pascal Joly +41 more
TL;DR: Corticosteroids with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris and the efficacy of adjUvant therapies in minimizing steroid‐related adverse events (AEs) is unproven.